within Pharmacolibrary.Drugs.ATC.L;

model L02BX02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.97,
    Cl             = 0.014666666666666666,
    adminDuration  = 600,
    adminMass      = 0.24,
    adminCount     = 1,
    Vd             = 0.019,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Degarelix is a selective gonadotropin-releasing hormone (GnRH) receptor antagonist used in the treatment of advanced hormone-dependent prostate cancer in men. It acts by suppressing the production of luteinizing hormone and subsequently testosterone without causing a testosterone surge. Degarelix is currently approved for medical use in many countries for prostate cancer.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adult males with prostate cancer following subcutaneous administration.</p><h4>References</h4><ol><li><p>Steinberg, M (2009). Degarelix: a gonadotropin-releasing hormone antagonist for the management of prostate cancer. <i>Clinical therapeutics</i> 31 Pt 2 2312–2331. DOI:<a href=&quot;https://doi.org/10.1016/j.clinthera.2009.11.009&quot;>10.1016/j.clinthera.2009.11.009</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/20110043/&quot;>https://pubmed.ncbi.nlm.nih.gov/20110043</a></p></li><li><p>Agersø, H, et al., &amp; Karlsson, MO (2003). The dosing solution influence on the pharmacokinetics of degarelix, a new GnRH antagonist, after s.c. administration to beagle dogs. <i>European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences</i> 20(3) 335–340. DOI:<a href=&quot;https://doi.org/10.1016/j.ejps.2003.08.001&quot;>10.1016/j.ejps.2003.08.001</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/14592699/&quot;>https://pubmed.ncbi.nlm.nih.gov/14592699</a></p></li><li><p>Doehn, C, et al., &amp; Jocham, D (2006). Drug evaluation: Degarelix--a potential new therapy for prostate cancer. <i>IDrugs : the investigational drugs journal</i> 9(8) 565–572. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/16871466/&quot;>https://pubmed.ncbi.nlm.nih.gov/16871466</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L02BX02;
